FORA Capital’s Esperion Therapeutics ESPR Stock Holding History

FORA Capital’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-5,855	Closed	-$300K	–	743
2020 Q2	$300K	Buy	5,855 +516	+10%	+$21.6K	0.1%	251
2020 Q1	$168K	Buy	+5,339	New	+$282K	0.04%	488

Other funds holding ESPR

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

FORA Capital's ESPR Position: Q3 2020 in Review

FORA Capital sold out of Esperion Therapeutics (ESPR) in Q3 2020, closing a stake of 5,855 shares — an estimated $300K sold.

FORA Capital first reported a position in ESPR in Q1 2020 and held it in 2 quarters. The position peaked at $300K in Q2 2020. 166 funds tracked by Wall St. Rank hold ESPR as of Q3 2020.

FORA Capital reported no remaining Esperion Therapeutics position as of Q3 2020 after selling out during the quarter.
FORA Capital sold 5,855 Esperion Therapeutics shares in Q3 2020, an estimated $300K.
FORA Capital first reported a position in Esperion Therapeutics in Q1 2020 and held it in 2 quarters.
FORA Capital's Esperion Therapeutics position peaked at $300K in Q2 2020.
166 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2020.

Based on FORA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.